Seasonal influenza vaccine - Dynavax Technologies
Latest Information Update: 03 Dec 2021
At a glance
- Originator Dynavax Technologies
- Class Adjuvants; Influenza virus vaccines
- Mechanism of Action Immunostimulants; Toll-like receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 01 Nov 2021 Seasonal influenza vaccine - Dynavax Technologies is available for licensing as of 01 Nov 2021. https://www.dynavax.com/ongoing-studies/#partners (Dynavax Technologies pipeline, November 2021)
- 01 Nov 2021 Preclinical trials in Influenza virus infections (Prevention) in USA (unspecified route) (Dynavax Technologies pipeline, November 2021)